ABSTRACT
Because it is believed that a number of disease pathologies are involved in AD development, a novel strategy with multifunctional DMDs that aim simultaneously at several therapeutic targets may provide more effective approaches to slow or stop the initiation and progression of AD. As evidence, the combination therapy of cholinesterase inhibitors and NMDA receptor antagonists, which act differently on the chemistry of the brain, shows a statistically signifi cant benefi t as compared with mono-therapy with regard to measures of cognitive function, activities of daily living, behavior and clinical global status (Tariot et al. 2004). A multifunctional DMD may also be safer than a combination of several mono-functional drugs for AD treatment so as to avoid drug interactions and limit the sideeffects of each drug.
